UCB SA (OTCMKTS:UCBJF – Get Free Report)’s stock price was up 13.5% on Thursday . The company traded as high as $149.88 and last traded at $149.85. Approximately 200 shares were traded during mid-day trading, a decline of 78% from the average daily volume of 902 shares. The stock had previously closed at $132.00.
UCB Stock Performance
The firm has a 50 day simple moving average of $131.98 and a 200-day simple moving average of $116.91.
UCB Company Profile
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Featured Articles
- Five stocks we like better than UCB
- How to Start Investing in Real Estate
- This Cybersecurity Stock Gains Analysts’ Favor for Strong Growth
- The How And Why of Investing in Oil Stocks
- Parabolic Rise of This Stock Shows No Signs of Slowing
- 3 Small Caps With Big Return Potential
- Risk Tolerance vs. Risk Appetite: Key Differences
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
